Trimetazidine Stella MR

Trimetazidine diHCl

Add-on therapy for symptomatic treatment of adults w/ stable angina pectoris who are inadequately controlled by or intolerant to 1st line antianginal therapies.

1 tab bd. Elderly &/or patient w/ moderate renal impairment (CrCl 30-60 mL/min) 1 tab in the morning.

Should be taken with food: Swallow whole, do not chew/crush.

Hypersensitivity. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, & other related movement disorders. Severe renal impairment (CrCl <30 mL/min).

Use for symptomatic treatment of tinnitus, vertigo & visual field disturbances should no longer be authorized. Not a curative treatment for angina attacks. Not indicated as initial treatment for unstable angina or MI, nor in the prehospital phase or during the 1st days of hospitalisation. Can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), especially in elderly patients. W/draw if movement disorders (eg, parkinsonian symptoms, restless leg syndrome, tremors, gait instability) occur. Consult a neurologist if parkinsonian symptoms persist >4 mth after discontinuation. Falls may occur in patients taking antihypertensive treatment. Patients who are predisposed to closed-angle glaucoma. May affect ability to drive & use machines. Patients w/ moderate renal impairment. Preferable to avoid use during pregnancy. Should not be used during lactation. Childn <18 yr. Elderly >75 yr.

Dizziness, headache; abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; rash, pruritus, urticaria; asthenia.

Anti-Anginal Drugs

C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.

P₁S₁S₃